NDC 68151-2299 Minocycline Hydrochloride

The NDC code 68151-2299 is assigned by the FDA to the product Minocycline Hydrochloride which is product labeled by Carilion Materials Management. The product's dosage form is . The product is distributed in a single package with assigned NDC code 68151-2299-5 1 capsule in 1 package . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae.Respiratory tract infections caused by Mycoplasma pneumoniae.Lymphogranuloma venereum caused by Chlamydia trachomatis.Psittacosis (Ornithosis) due to Chlamydia psittaci.Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatisInclusion conjunctivitis caused by Chlamydia trachomatis.Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticumChlamydia trachomatis.Relapsing fever due to Borrelia recurrentis.Chancroid caused by Haemophilus ducreyi.Plague due to Yersinia pestis.Tularemia due to Francisella tularensis.Cholera caused by Vibrio cholerae.Campylobacter fetus infections caused by Campylobacter fetus.Brucellosis due to species (in conjunction with streptomycin). BrucellaBartonellosis due to Bartonella bacilliformis.Granuloma inguinale caused by Calymmatobacterium granulomatis.Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:Escherichia coli.Enterobacter aerogenes.species. Shigellaspecies. AcinetobacterRespiratory tract infections caused by Haemophilus influenzae.Respiratory tract and urinary tract infections caused by species. KlebsiellaMinocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:Upper respiratory tract infections caused by . Streptococcus pneumoniaeSkin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus.When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections:Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeaeInfections in women caused by . Neisseria gonorrhoeaeSyphilis caused by subspecies Treponema pallidumpallidum.Yaws caused by subspecies Treponema pallidumpertenue.Listeriosis due to Listeria monocytogenes.Anthrax due to . Bacillus anthracisVincent’s infection caused by Fusobacterium fusiforme.Actinomycosis caused by Actinomyces israelii.Infections caused by species Clostridium.In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis,In severe minocycline may be useful adjunctive therapy. acne,Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidisOral minocycline is not indicated for the treatment of meningococcal infection.Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum.To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

• RxCUI: 197984 - minocycline HCl 100 MG Oral Capsule
• RxCUI: 197984 - minocycline 100 MG Oral Capsule
• RxCUI: 197984 - minocycline (as minocycline HCl) 100 MG Oral Capsule